Data:2009-12-12 2:34
Category: Money tips Release Date: 2007-04-20
On the real medicine (600,607 market, information, reviews, search) the actual controller of the real group is wholly owned by the Shanghai Municipal Government a comprehensive enterprise group. Shanghai Municipal Government in Hong Kong as a window business, the Group has a rich industrial real resources, real estate, medicine, and international trade to become the three pillars of the Group of the sex industry. On the real medical textile enterprises from the initial phase transition to pharmaceutical holding enterprise, and become the real assets of the Group of medicine integrated platform.
On the real medicine has extensive medical assets, which often focus on drug shares and assets of Guangdong Tempe. Pharmaceutical shares often maintained a rapid growth in net profit is expected to remain for at least the next three years the growth rate of 15-20%. In addition, often the main source of profit for drug shares often pharmaceutical companies also entered the National Food and Drug Administration of the first urban communities, rural basic medicine list of designated production enterprise. Guangdong, Tempe is the current domestic production of protein products in human urine, one of the largest manufacturers, the main products include a class of drugs Kai Li Kang, second-class medicine Ulinastatin as well as some export bulk drugs and so on. Currently Ulinastatin Guangdong Tempe major source of revenue and profits, the state-Kai Li Kang a class of drugs is well under way to promote among the varieties outbreak potential. The company's future development strategy of the group's assets, an integrated platform for medicine, and in 2007, this process will accelerate. Through the placement of medical assets of high-quality, focused pharmaceutical industry, the real medicine to enhance its competitive position in the industry.
Ju-Ying Hai Tong Securities analyst expects the company's 2006-2008 earnings per share were 0.32 yuan, 0.36 yuan and 0.61 yuan (diluted). In 2008, on the basis of the performance to give 25-30 times the valuation of the company's reasonable price range -18.30 to 15.25 yuan yuan, maintaining a "buy" investment rating.
